CAB-AXL-ADC

BIOLOGICAL2 trials

Sponsors

BioAtla, Inc.

Conditions

MyxofibrosarcomaNon-Small-Cell Lung CancerUndifferentiated Pleomorphic Sarcoma

Phase 1

CAB-AXL-ADC Safety and Efficacy Study in Adult and Adolescent Patients With Sarcoma

CompletedNCT03425279

BioAtla, Inc.Myxofibrosarcoma, Undifferentiated Pleomorphic Sarcoma

Start: 2018-02-15End: 2025-01-08Updated: 2025-09-23

Phase 2

CAB-AXL-ADC Safety and Efficacy Study in Adults With NSCLC

CompletedNCT04681131

BioAtla, Inc.Non-Small-Cell Lung Cancer

Start: 2021-03-17End: 2025-07-09Updated: 2025-09-25

Related Papers

Overall survival analysis of a heavily pretreated population of patients with bone sarcomas treated with mecbotamab vedotin, a conditionally binding ADC targeting AXL.

Journal of Clinical Oncology2026-05-27

Population pharmacokinetic and exposure-response safety analyses of mecbotamab vedotin (BA3011) in patients with advanced solid tumors.

Journal of Clinical Oncology2023-06-013 citations